{"id":"W2020431842","doi":"10.1016/j.clml.2012.08.003","title":"An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma","year":2012,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary; Beatrice Hunter Cancer Research Institute; Saint John Regional Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"Onyx Pharmaceuticals","keywords":"Carfilzomib; Medicine; Multiple myeloma; Bortezomib; Lenalidomide; Internal medicine; Thalidomide; Refractory (planetary science); Adverse effect; Regimen; Clinical endpoint; Phases of clinical research; Proteasome inhibitor; Anemia; Oncology; Surgery; Clinical trial; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002120474,0.002373157,0.003529286,0.0006366941,0.0007014397,0.001226875,0.001463571,0.001699417,0.004866842],"category_scores_gemma":[0.001173212,0.0009171299,0.001816292,0.0005654592,0.00218639,0.001786346,0.0005022316,0.005934832,0.001435077],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00126551,"about_ca_system_score_gemma":0.00251863,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001919029,"about_ca_topic_score_gemma":0.003966215,"domain_scores_codex":[0.9993562,0.0002906114,0.00002236735,0.0001021096,0.00004701399,0.0001816068],"domain_scores_gemma":[0.9987871,0.0002089023,0.0001415266,0.0001163012,0.00005964131,0.0006864474],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8303282,0.0825691,0.003027366,0.000468515,0.0007914387,0.0001907053,0.0002415891,0.001771387,0.02812409,0.0002803481,0.003222897,0.04898437],"study_design_scores_gemma":[0.6492838,0.3413764,0.005704093,0.00001094639,0.0002089718,0.0001240126,0.00004579994,0.0007522592,0.001285955,0.0001587203,0.001022007,0.00002715568],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9912827,0.001169954,0.0008010677,0.0006970514,0.0002104879,0.002740238,0.001191532,0.000189533,0.001717533],"genre_scores_gemma":[0.9868845,0.001151889,0.002139965,0.0009932818,0.0003801452,0.003319927,0.002347295,0.00005758246,0.002725462],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004866842,"threshold_uncertainty_score":0.01628119,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09475273562003522,"score_gpt":0.3770711989469108,"score_spread":0.2823184633268755,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}